Ananda Pharma PLC - Ananda attending Cannabinoid Summit

16 September 2025

ANANDA PHARMA PLC

("Ananda" or the "Company")

Ananda to attend 8^th Cannabinoid & Endocannabinoid Drug Development Summit

Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions and focused on endometriosis, chemotherapy induced peripheral neuropathy (CIPN) and epilepsy is pleased to announce that CEO Melissa Sturgess will be attending the 8th Cannabinoid & Endocannabinoid Drug Development Summit, taking place in Boston, Massachusetts on 15-16, October.

On 15 October, Melissa will give a presentation titled: "Advancing Botanical Cannabidiol Drugs: Insights from Endometriosis Clinical Development" and will outline:

-     Ananda's strategic approach to CBD drug development using naturally derived CBD isolate and its advantages

-     The case for higher dosing over bioavailability modifications to improve drug efficacy

-     Ananda's endometriosis program as a case study to highlight the clinical and regulatory strategies that enabled fast progression into human trials and why this model is important for women's health

Following this presentation, Melissa will participate in a panel discussion titled "Explore How Industry Leaders are Navigating the Challenges of Bringing Cannabinoid Based Therapies to Women's Health". The panel will:

-     Explore effective strategies to engage and educate patients, clinicians, and advocacy groups to drive awareness and increase participation in cannabinoid clinical trials for endometriosis

-     Identify the key regulatory, societal, and commercial barriers limiting patient access to cannabinoid-based therapies and evaluating solutions

-     Examine how industry collaboration, policy evolution, and patient advocacy can work together to accelerate the responsible adoption of cannabinoid treatments in women's health

Melissa Sturgess, CEO, commented: "Endometriosis remains one of the most underdiagnosed and underserved conditions in women's health - yet it affects millions. At Ananda Pharma, we're proud to be pushing boundaries with our MRX1 CBD formulation, now in clinical trials, to bring real hope to those who have waited far too long for answers. I look forward to continuing the conversation around advancing innovation in women's health."

About the Cannabinoid & Endocannabinoid Drug Development Summit

In an era of increasing scientific validation and evolving regulatory frameworks, the

demand for rigorously tested and approved cannabinoid therapies is surging. This summit serves as the crucial venue for biopharma senior decision makers, research scientists, clinical development, and regulatory affairs experts who are actively prioritizing and shaping the future of cannabinoid prescription therapies.

Now in its 8th year, the Cannabinoid & Endocannabinoid Drug Development Summit features a new business and investor panel, IP protection sessions, and interactive regulatory discussions, plus insights from the past year's key milestones and clinical lessons shared by leading biotech innovators.

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn:  https://www.linkedin.com/company/anandapharma

·              X: https://twitter.com/AnandaPlc

-Ends-

The Directors of the Company accept responsibility for the contents of this announcement.

For more information please contact:

https://investors.anandapharma.co.uk/link/PljOge